THC Image: Medical Marijuana Doctors Enfield CT

Certified Medical Marijuana Prescriber

Registered with the Connecticut Prescription Monitoring Program
Medical research and doctors across the country have found medical marijuana helpful in the management of a broad variety of symptoms. Symptoms and conditions where medical marijuana shows promise include neuropathic pain, cancer pain, nausea, intractable headache, Tourette's syndrome, and glaucoma - to name a few. As of 2019, medical marijuana is approved in the state of Connecticut for the treatment of 36 different conditions for adults and 10 conditions for patients under age 18. In some cases, medical marijuana has a unique pharmacological action which makes it effective in ways that are out of reach of other medications. In other cases, synthetic medications are available, but the side effects and risks of medical marijuana may be preferable to those of other medications. Medical marijuana has been used to reduce or replace the use of opioids, benzodiazeines, and dopamine antagonists such as haloperidol and olanzapine.
Our Process for Treatment with Medical Marijuana

Primary Spine & Rehab has certification in medical marijuana. We can prescribe medical marijuana and provide annual certification for medical marijuana cards issued by the state of Connecticut. We prescribe medical marijuana as part of in-person treatment for a debilitating condition. For this prescription, patients must be Connecticut residents and have a condition for which medical marijuana is approved.

Medical Marijuana Prescription

Medical Marijuana is Approved in Connecticut for the Following Conditions

*Last updated 12/21/19.
Medical Marijuana for Adults
  • Cancer (Effective 2012)
  • Glaucoma (Effective 2012)
  • Positive Status for Human Immunodeficiency Virus or Acquired Immune Deficiency Syndrome (Effective 2012)
  • Parkinson's Disease (Effective 2012)
  • Multiple Sclerosis (Effective 2012)
  • Damage to the Nervous Tissue of the Spinal Cord with Objective Neurological Indication of Intractable Spasticity (Effective 2012)
  • Epilepsy (Effective 2012)
  • Cachexia (Effective 2012)
  • Wasting Syndrome (Effective 2012)
  • Crohn's Disease (Effective 2012)
  • Post-Traumatic Stress Disorder (Effective 2012)
  • Sickle Cell Disease (Effective 2016)*
  • Post Laminectomy Syndrome with Chronic Radiculopathy (Effective 2016)*
  • Severe Psoriasis and Psoriatic Arthritis (Effective 2016)*
  • Amyotrophic Lateral Sclerosis (Effective 2016)*
  • Ulcerative Colitis (Effective 2016)*
  • Complex Regional Pain Syndrome, Type 1 and Type II (Effective 2016)*
  • Cerebral Palsy (Effective 2016)
  • Cystic Fibrosis (Effective 2016)
  • Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)
  • Terminal Illness Requiring End-Of-Life Care (Effective 2016)
  • Uncontrolled Intractable Seizure Disorder (Effective 2016)
  • Spasticity or Neuropathic Pain Associated with Fibromyalgia (Effective 2018)*
  • Severe Rheumatoid Arthritis (Effective 2018)*
  • Post Herpetic Neuralgia (Effective 2018)*
  • Hydrocephalus with Intractable Headache (Effective 2018)*
  • Intractable Headache Syndromes (Effective 2018)*
  • Neuropathic Facial Pain (Effective 2018)*
  • Muscular Dystrophy (Effective 2018)*
  • Osteogenesis Imperfecta (Effective 2018)*
  • Chronic Neuropathic Pain Associated with Degenerative Spinal Disorders (Effective 2018)*
  • Interstitial Cystitis (Effective 2019)*
  • MALS Syndrome (Median Arcuate Ligament Syndrome) (Effective 2019)*
  • Vulvodynia and Vulvar Burning (Effective 2019)*
  • Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*
  • Tourette Syndrome (Effective 2019)*
Medical Marijuana for Patients Under Age 18
  • Cerebral Palsy (Effective 2016)
  • Cystic Fibrosis (Effective 2016)
  • Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)
  • Severe Epilepsy (Effective 2016)
  • Terminal Illness Requiring End-Of-Life Care (Effective 2016)
  • Uncontrolled Intractable Seizure Disorder (Effective 2016)
  • Muscular Dystrophy (Effective 2018)*
  • Osteogenesis Imperfecta (Effective 2018)*
  • Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*
  • Tourette Syndrome for patients who have failed standard medical treatment (Effective 2019)*
You can check for updates to these lists at ct.gov.